CG Oncology to Present Positive Final Results from Phase 2

  CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.

https://www.globenewswire.com/news-release/2024/05/24/2887943/0/en/CG-Oncology-to-Present-Positive-Final-Results-from-Phase-2-CORE-001-Study-of-Cretostimogene-Grenadenorepvec-in-Combination-with-Pembrolizumab-in-BCG-Unresponsive-High-Risk-NMIBC-at.html